Search results
Measles vaccine more likely to not work in kids born by C-section: study
KTBS Shreveport· 11 hours agoThe measles vaccine is more than twice as likely not to work in children born by Caesarean section,...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 hours agoWALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that Marc Elia, Chairman of the Invivyd Board
Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 11 hours agoInvivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript May 11, 2024 Invivyd, Inc. isn’t one of...
Experimental Type 1 Diabetes Drug Shields Pancreas Cells from the Usual Crippling Immune System...
GoodNewsNetwork· 6 days agoScientists at Johns Hopkins say that an experimental antibody drug appears to prevent and reverse the onset of type 1 diabetes in mice—and often lengthen their lives. The ...
A third COVID vaccine dose improves defense for some clinically extremely vulnerable patients
Medical Xpress· 5 days agoThis trial opened in 11 hospitals across the UK and recruited 804 patients across nine disease...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 9 hours agoThe study was testing whether a combination of the company’s flagship cancer drug Keytruda and its...
Birth by C-section more than doubles odds of measles vaccine failure
Science Daily· 18 hours agoFailure of the vaccine means that the child's immune system does not produce antibodies to fight against measles infection, so they remain susceptible to the disease. A second measles jab was ...
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
Clinical Trials Arena via Yahoo Finance· 15 hours agoIt has been approved to treat a variety of cancers, including renal cell carcinoma, gastric cancer,...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer...
FOX 23 News Albany· 2 hours agoKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing...
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Pharmaceutical Technology via Yahoo Finance· 10 hours agoThe trials were conducted in adults, but the sBLA also has safety data on Dupixent’s use in other...